AstraZeneca PLC American Depositary Shares (AZN)
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market.
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.
Exclusive: AstraZeneca pauses $270 million investment in Britain
Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said, the latest drugmaker to retreat from Britain.
AstraZeneca to seek approval for blood pressure drug by year-end
AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker's long-term sales strategy.
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
AstraZeneca: Great Portfolio, But Not A Great Price
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
Ex-dividend day weighs heavily on the FTSE this week
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:NWG) and Rolls-Royce Holdings PLC (LSE:RR.). There were 18.3 points collectively shaved off the index as a result of 12 blue-chips going ex-dividend on the day, when investors who purchase shares today are no longer entitled to their latest dividend payouts.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca gets clean bill of health from leading investment bank
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results. The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Iskra Reic - Executive Vice President of International Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Pascal Claude Roland Soriot - CEO & Executive Director Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Susan Mary Galbraith - Executive Vice President of Oncology R&D Conference Call Participants Gonzalo Artiach Castanon - Danske Bank A/S, Research Division James Daniel Gordon - JPMorgan Chase & Co, Research Division Luisa Caroline Hector - Joh.
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter revenue of $14.46 billion, up 12%, driven by double-digit gains in oncology and biopharmaceuticals.
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
